Pfizer to Buy Rest of Biohaven for $11.6 Billion
Pfizer agree to buy the rest of the Biohaven Pharmaceutical Holding for about $11.6 billion, deploying the cash piled up from the sale of Covid-19 to buy a new migraine drug.
Pfizer said it will pay $148.50 a share in cash for shares of Biohaven it doesn’t already own, nearly 79% more than Monday’s closing price of $83.14 for New Haven, Conn. ., Drug manufacturer.
https://www.wsj.com/articles/pfizer-to-buy-rest-of-biohaven-for-11-6-billion-11652181121?mod=pls_whats_news_us_business_f Pfizer to Buy Rest of Biohaven for $11.6 Billion
